ReviR Therapeutics

ReviR Therapeutics (溪砾科技) is an AI+RNA drug discovery startup founded in 2021 that applies machine learning to RNA biology, built around its voyageR™ AI technology platform for candidate compound screening and development . The company has raised a $30 million Series A round led by Dragonstone Capital in July 2024, with continued follow-on from existing shareholders including 5Y Capital and DH Healthcare , following an earlier Pre-A round in early 2022 also backed by Shunwei Capital, Yunqi Capital and others . Beyond its investor base, ReviR has secured non-dilutive funding from disease-focused foundations, including a partnership with the CMT Research Foundation and, as of late 2024, a collaboration with the Kennedy's Disease Association to advance therapies for Kennedy's Disease .